AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $16.66, but opened at $17.45. AnaptysBio shares last traded at $17.22, with a volume of 119,104 shares trading hands.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. BTIG Research cut AnaptysBio from a "buy" rating to a "neutral" rating in a research report on Monday, December 2nd. Wolfe Research started coverage on shares of AnaptysBio in a research report on Tuesday. They issued an "outperform" rating and a $25.00 price objective on the stock. JPMorgan Chase & Co. cut their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an "overweight" rating for the company in a research report on Thursday, December 19th. HC Wainwright reaffirmed a "neutral" rating and issued a $19.00 target price on shares of AnaptysBio in a report on Tuesday. Finally, UBS Group increased their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, AnaptysBio has a consensus rating of "Moderate Buy" and a consensus target price of $40.08.
Check Out Our Latest Stock Analysis on AnaptysBio
AnaptysBio Trading Down 9.3 %
The firm has a 50 day moving average of $16.69 and a two-hundred day moving average of $26.62. The stock has a market capitalization of $443.67 million and a PE ratio of -2.40.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Equities research analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.
Insider Buying and Selling at AnaptysBio
In other news, Director Ecor1 Capital, Llc purchased 6,646 shares of the firm's stock in a transaction on Thursday, January 2nd. The shares were bought at an average cost of $12.95 per share, with a total value of $86,065.70. Following the purchase, the director now directly owns 7,880,094 shares of the company's stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 33.70% of the stock is currently owned by insiders.
Hedge Funds Weigh In On AnaptysBio
Institutional investors and hedge funds have recently modified their holdings of the company. Values First Advisors Inc. purchased a new position in shares of AnaptysBio during the 3rd quarter worth $49,000. nVerses Capital LLC lifted its position in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock worth $54,000 after buying an additional 1,400 shares during the period. AlphaQuest LLC boosted its stake in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after buying an additional 4,237 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock valued at $85,000 after buying an additional 644 shares during the period. Finally, Point72 DIFC Ltd increased its stake in shares of AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company's stock valued at $205,000 after acquiring an additional 5,342 shares during the last quarter.
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Featured Stories
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
